Cybin Announces FDA Clearance to Initiate a Phase 2a Study of CYB004 in Generalized Anxiety Disorder
- Recently announced positive Phase 1 topline safety, pharmacokinetic (“PK”) and pharmacodynamic (“PD”) data show that intravenous (“IV”) CYB004 demonstrated robust and rapid-onset psychedelic effects ...
A clinical trial’s encouraging results won US Food and Drug Administration breakthrough therapy status for an LSD formulation to treat generalized anxiety disorder, Mind Medicine Inc. announced ...
A rigorous new study finds that a single dose of LSD can ease anxiety and depression for months. The study involved 198 adults with generalized anxiety disorder, or GAD, a disabling form of anxiety ...
SAN ANTONIO, May 27, 2026 /PRNewswire/ -- A peer-reviewed case study published in the journal Transcranial Magnetic Stimulation reports that an accelerated transcranial magnetic stimulation (aTMS) ...
Hello, and welcome to the Definium Therapeutics Phase III Voyage Topline Results Call. [Operator Instructions] As a reminder, this conference is being recorded today. If you have any objections, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results